Avicularin induces apoptosis in NSCLC by promoting USP7-mediated degradation of FOXM1
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04529-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Jiangyue Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, China. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ubiquitin-Specific Peptidase 7. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Fund of Ningbo Yinzhou Science and Technology Bureau.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for novel and effective therapeutic strategies. Avicularin (Avi), a naturally occurring flavonoid, has been shown to reduce cell viability and induce caspase-dependent apoptosis in NSCLC cells, while exhibiting minimal cytotoxicity toward normal bronchial epithelial cells. Mechanistically, Avi selectively decreases FOXM1 protein expression without affecting its mRNA levels, suggesting post-transcriptional regulation. Further investigation revealed that Avi promotes K48-linked polyubiquitination of FOXM1 and disrupts its interaction with the deubiquitinase USP7, thereby destabilizing FOXM1 and enhancing apoptotic signaling. Notably, overexpression of either FOXM1 or USP7 attenuated Avi-induced cytotoxicity. In vivo, Avi markedly inhibited tumor growth in A549 xenograft models without inducing systemic toxicity. Moreover, Avi enhanced the anti-tumor effects of gefitinib, leading to greater apoptosis and reduced cell viability compared to either agent alone. Collectively, these findings demonstrate that Avi exerts potent anti-NSCLC activity by facilitating USP7-dependent degradation of FOXM1 and highlight its potential as both a monotherapy and an adjuvant to EGFR-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, China.
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Zhejiang, China.
- Department of Pulmonary Surgery, Zhejiang Cancer Hospital, Zhejiang, China.
- Department of Integrated Traditional Chinese and Western Medicine Oncology, People's Hospital Affiliated to Ningbo University, Zhejiang, China.
- Xihu District Hangzhou SanDu Town Community Health Service Center, Hangzhou, China.
- Department of Pulmonary Surgery, Zhejiang Cancer Hospital, Zhejiang, China. hzltb123@163.com.
Förderung
- Fund of Ningbo Yinzhou Science and Technology Bureau
Zitieren
APA
Du, J., Yu, K., Zeng, J., Ma, L., Yu, T., Yu, R., & Luo, T. (2026). Avicularin induces apoptosis in NSCLC by promoting USP7-mediated degradation of FOXM1. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04529-6
Vancouver
Du J, Yu K, Zeng J, Ma L, Yu T, Yu R, et al. Avicularin induces apoptosis in NSCLC by promoting USP7-mediated degradation of FOXM1. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04529-6
BibTeX
@article{Du2026,
author = {Du, Jiangyue and Yu, Kuai and Zeng, Jian and Ma, Lijuan and Yu, Tingting and Yu, Rui and Luo, Taobo},
title = {Avicularin induces apoptosis in NSCLC by promoting USP7-mediated degradation of FOXM1},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04529-6}
}
EUVIMED